aprpАктуальные проблемы российского праваActual Problems of Russian Law1994-14712782-1862MSAL10.17803/1994-1471.2026.183.2.137-149aprp-5679Research ArticleМЕДИЦИНСКОЕ ПРАВОMEDICAL LAWВ поисках оптимальной модели правового регулирования нейрогенетики в Российской ФедерацииIn Search of an Optimal Model for the Legal Regulation of Neurogenetics in the Russian FederationБергЛ. Н.BergL. N.

Людмила Николаевна Берг, доктор юридических наук, профессор, профессор кафедры

кафедра теории государства и права имени С.С. Алексеева

620137; Комсомольская ул., д. 21; Екатеринбург

Lyudmila N. Berg, Dr. Sci. (Law), Professor

Department of Theory of State and Law named after S.S. Alexeev

Ekaterinburg

mila-berg@mail.ruУральский государственный юридический университет имени В.Ф. ЯковлеваUral State Law University named after V.F. Yakovlev202615032026212137149Copyright © Берг Л.Н., 20262026Берг Л.Н.Berg L.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://aprp.msal.ru/jour/article/view/5679

   Нейрогенетика — быстро развивающаяся область генетики, важная для диагностики, лечения и профилактики неврологических расстройств. В статье подробно рассматриваются правовые аспекты нейрогенетики, относящиеся к порядку проведения нейрогенетического тестирования и использования его результатов для развития персонализированной медицины, анализируются виды нейрогенетического тестирования, проблемные вопросы получения информированного согласия, проведения неинвазивного пренатального тестирования. По мнению автора, потенциал использования нейрогенетики непосредственно зависит от надлежащего правового регулирования порядка проведения нейрогенетического тестирования, с помощью которого могут быть выявлены специфические генетические мутации, связанные с возникновением неврологических расстройств. Вместе с тем многие аспекты нейрогенетического тестирования, включая конфиденциальность, генетическую дискриминацию и порядок сообщения результатов тестирования, требуют законодательной регламентации. Адекватное правовое регулирование позволитраскрыться исследовательскому потенциалу нейрогенетического тестирования, новейших диагностических, профилактических и клинических инструментов, адаптированных к индивидуальным нейрогенетическим профилям. Нормативная регламентация применения нейрогенетики будет способствовать повышению доступности нейрогенетического тестирования и лечения, критически важных для уменьшения бремени неврологических расстройств.

   Neurogenetics is a rapidly developing field of genetics that is important for the diagnosis, treatment, and prevention of neurological disorders. The paper scrutinizes the legal aspects of neurogenetics related to the procedure for conducting neurogenetic testing and the use of its results for the development of personalized medicine. The author analyzes the types of neurogenetic testing, problematic issues of obtaining informed consent, and conducting non-invasive prenatal testing. According to the author, the potential use of neurogenetics directly depends on proper legal regulation of the procedure for conducting neurogenetic testing, which may be helpful in identifying specific genetic mutations associated with the occurrence of neurological disorders. However, many aspects of neurogenetic testing, including confidentiality, genetic discrimination, and the procedure for reporting test results, require legislative regulation. Adequate legal regulation will enable the full potential of neurogenetic testing, including the latest diagnostic, preventative, and clinical tools tailored to individual neurogenetic profiles. Regulatory guidance on the use of neurogenetics will facilitate increased access to neurogenetic testing and treatment, which are critical to reducing the burden of neurological disorders.

нейрогенетиканейрогенетическое тестированиеинформированное согласиеперсонализированная медицинагенетическая дискриминациягенетическая информациягеномная информацияконфиденциальность геномных данныхправовое воздействиеправовое регулированиеneurogeneticsneurogenetic testinginformed consentpersonalized medicinegenetic discriminationgenetic informationgenomic informationconfidentiality of genomic datalegal impactlegal regulationReferencesБерг Л. Н. Конфиденциальность геномной информации и право на доступ к научным знаниям: вопросы соотношения // Lex russica (Русский закон). — 2024. — Т. 77. — № 10. — С. 93–101.Berg L. N. Konfidentsialnost genomnoy informatsii i pravo na dostup k nauchnym znaniyam: voprosy sootnosheniya // Lex russica (Russkiy zakon). — 2024. — T. 77. — № 10. — S. 93–101.Берг Л. Н., Голубцов В. Г. Правовые аспекты использования эпигенетической информации: вопросы конфиденциальности, дискриминации и личной ответственности // Вестник Пермского университета. Юридические науки. — 2024. — № 3. — С. 373–381.Berg L. N., Golubtsov V. G. Pravovye aspekty ispolzovaniya epigeneticheskoy informatsii: voprosy konfidentsialnosti, diskriminatsii i lichnoy otvetstvennosti // Vestnik Permskogo universiteta. Yuridicheskie nauki. — 2024. — № 3. — S. 373–381.Ashcroft R. Principles of Health Care Ethics. — Wiley, 2007.Ashcroft R. Principles of Health Care Ethics. — Wiley, 2007.Beattie B. Consent in Alzheimer’s Disease Research: Risk/Benefit Factors // The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. — 2007. — Vol. 34. — P. 27–31.Beattie B. Consent in Alzheimer’s Disease Research: Risk/Benefit Factors // The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. — 2007. — Vol. 34. — P. 27–31.Botkin J. Points to consider: ethical, legal and psychosocial implications of genetic testing in children and adolescents // American journal of human genetics. — 2015. — Vol. 97. — No. 1. — P. 6–21.Botkin J. Points to consider: ethical, legal and psychosocial implications of genetic testing in children and adolescents // American journal of human genetics. — 2015. — Vol. 97. — No. 1. — P. 6–21.Carrillo M. Can we prevent Alzheimer’s disease? Secondary «prevention» trials in Alzheimer’s disease // Alzheimer’s & dementia : the journal of the Alzheimer’s Association. — 2013. — Vol. 9. — No. 2. — P. 123–131.Carrillo M. Can we prevent Alzheimer’s disease? Secondary «prevention» trials in Alzheimer’s disease // Alzheimer’s & dementia: the journal of the Alzheimer’s Association. — 2013. — Vol. 9. — No. 2. — P. 123–131.Gandy S. APOE e4 status and traumatic brain injury on the gridiron or the battlefield // Science Translational Medicine. — 2012. — Vol. 4. — No. 134. — P. 1–3.Gandy S. APOE e4 status and traumatic brain injury on the gridiron or the battlefield // Science Translational Medicine. — 2012. — Vol. 4. — No. 134. — P. 1–3.Haibo T. Medical Data Management on Blockchain with Privacy // Journal of Medical Systems. — 2019. — Vol. 43. — No. 10. — P. 2–6.Haibo T. Medical Data Management on Blockchain with Privacy // Journal of Medical Systems. — 2019. — Vol. 43. — No. 10. — P. 2–6.Hedera P. Ethical principles and pitfalls of genetic testing for dementia // Journal of geriatric psychiatry and neurology. — 2001. — Vol. 14. — No. 4. — P. 213–221.Hedera P. Ethical principles and pitfalls of genetic testing for dementia // Journal of geriatric psychiatry and neurology. — 2001. — Vol. 14. — No. 4. — P. 213–221.Hercher L. Prenatal testing for adult-onset conditions: the position of the National Society of Genetic Counselors // Journal of genetic counseling. — 2016. — Vol. 25. — No. 6. — P. 1139–1145.Hercher L. Prenatal testing for adult-onset conditions: the position of the National Society of Genetic Counselors // Journal of genetic counseling. — 2016. — Vol. 25. — No. 6. — P. 1139–1145.Hoge S. Ethics and neuropsychiatric genetics : A review of major issues // The International Journal of Neuropsychopharmacology. — 2012. — Vol. 15. — No. 10. — P. 1547–1557.Hoge S. Ethics and neuropsychiatric genetics : A review of major issues // The International Journal of Neuropsychopharmacology. — 2012. — Vol. 15. — No. 10. — P. 1547–1557.Lautenbach D. Communicating genetic risk information for common disease in the era of genomic medicine // Annual Review of Genomics and Human Genetics. — 2013. — Vol. 14. — No. 1. — P. 491–513.Lautenbach D. Communicating genetic risk information for common disease in the era of genomic medicine // Annual Review of Genomics and Human Genetics. — 2013. — Vol. 14. — No. 1. — P. 491–513.Lynch D. Neurogenetics: Scientific and Clinical Advances. — CRC Press, 2006.Lynch D. Neurogenetics: Scientific and Clinical Advances. — CRC Press, 2006.Mariotti C. Predictive genetic tests in neurodegenerative disorders: A methodological approach integrating psychological counseling for at-risk individuals and referring clinicians // European Neurology. — 2010. — Vol. 64. — No. 1. — P. 33–41.Mariotti C. Predictive genetic tests in neurodegenerative disorders: A methodological approach integrating psychological counseling for at-risk individuals and referring clinicians // European Neurology. — 2010. — Vol. 64. — No. 1. — P. 33–41.McConkie-Rosell A. Genetic counseling for fragile X syndrome: updated recommendations of the national society of genetic counselors // Journal of Genetic Counseling. — 2005. — Vol. 14. — No. 4. — P. 249–270.McConkie-Rosell A. Genetic counseling for fragile X syndrome: updated recommendations of the national society of genetic counselors // Journal of Genetic Counseling. — 2005. — Vol. 14. — No. 4. — P. 249–270.McLean N. Ethical dilemmas associated with genetic testing: which are most commonly seen and how are they managed? // Genetics in medicine: official journal of the American College of Medical Genetics. — 2013. — Vol. 15. — No. 5. — P. 345–353.McLean N. Ethical dilemmas associated with genetic testing: which are most commonly seen and how are they managed? // Genetics in medicine : official journal of the American College of Medical Genetics. — 2013. — Vol. 15. — No. 5. — P. 345–353.Morrison P. Uptake of Huntington disease predictive testing in a complete population // Clinical Genetics. — 2011. — Vol. 80. — No. 3. — P. 281–286.Morrison P. Uptake of Huntington disease predictive testing in a complete population // Clinical Genetics. — 2011. — Vol. 80. — No. 3. — P. 281–286.Riedijk S. A decade of genetic counseling in frontotemporal dementia affected families: few counseling requests and much familial opposition to testing // Journal of Genetic Counseling. — 2009. — Vol. 18. — No. 4. — P. 350–356.Riedijk S. A decade of genetic counseling in frontotemporal dementia affected families: few counseling requests and much familial opposition to testing // Journal of Genetic Counseling. — 2009. — Vol. 18. — No. 4. — P. 350–356.Ross L. Technical report: Ethical and policy issues in genetic testing and screening of children // Genetics in medicine : official journal of the American College of Medical Genetics. — 2013. — Vol. 15. — No. 3. — P. 234–245.Ross L. Technical report: Ethical and policy issues in genetic testing and screening of children // Genetics in medicine : official journal of the American College of Medical Genetics. — 2013. — Vol. 15. — No. 3. — P. 234–245.Schneider S. Genetic testing for neurologic disorders // Seminars in neurology. — 2011. — Vol. 31. — P. 542–552.Schneider S. Genetic testing for neurologic disorders // Seminars in neurology. — 2011. — Vol. 31. — P. 542–552.Scult M. A brief introduction to the neurogenetics of cognition-emotion interactions // Current Opinion in Behavioral Sciences. — 2018. — Vol. 19. — P. 50–54.Scult M. A brief introduction to the neurogenetics of cognition-emotion interactions // Current Opinion in Behavioral Sciences. — 2018. — Vol. 19. — P. 50–54.Tassicker R. Problems assessing uptake of Huntington Disease predictive testing and a proposed solution // European Journal of Human Genetics. — 2009. — Vol. 17. — No. 1. — P. 66–70.Tassicker R. Problems assessing uptake of Huntington Disease predictive testing and a proposed solution // European Journal of Human Genetics. — 2009. — Vol. 17. — No. 1. — P. 66–70.Uhlmann W. Genetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues // Progress in Neurobiology. — 2013. — Vol. 110. — P. 89–101.Uhlmann W. Genetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues // Progress in Neurobiology. — 2013. — Vol. 110. — P. 89–101.

The authors declare that there are no conflicts of interest present.